Physician profile
Joseph Boecker
NPI 1346391505
$3,451.43
in general payments reported to CMS, 2019-2025
28 companies · $1,038 in 2025
The $1,038 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2021: $81.37 · 2022: $542 · 2023: $968 · 2024: $679 · 2025: $1,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,685.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $451.07 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $445.57 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $311.37 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $277.05 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $272.04 | 2022-2025 | |
| Abbvie INC. | $268.61 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.26 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $164.05 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $120.18 | 2019-2024 | Gardasil 9, M-M-R II, Vaxneuvance |
| Idorsia Pharmaceuticals US INC | $96.48 | 2023-2025 | Quviviq, Quviviq |
| Novartis Pharmaceuticals Corporation | $95.26 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $93.88 | 2022-2025 | |
| Abbott Laboratories | $92.02 | 2022-2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $71.62 | 2021-2025 | Nexletol |
| Amgen INC. | $70.21 | 2023-2024 | Otezla, Repatha, Krystexxa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $69.52 | 2019-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.08 | 2024-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $38.28 | 2022-2023 | Ajovy |
| Actelion Pharmaceuticals US, INC. | $33.62 | 2025 | Uptravi, Opsumit |
| Inspire Medical Systems, INC. | $27.02 | 2025 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $26.98 | 2023 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $26.47 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.85 | 2025 | Xifaxan |
| Dynavax Technologies Corporation | $21.08 | 2023 | Heplisav-B |
| Hologic Sales and Service, LLC | $19.68 | 2019 | |
| Supernus Pharmaceuticals, INC. | $15.82 | 2022 | |
| Heartflow, INC. | $15.74 | 2022 | |
| Currax Pharmaceuticals LLC | $15.62 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Boecker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.